• Home
  • Symposia
    • San Diego Dermatology Symposium
    • Dermatology Refresher Symposium for NPs and PAs
    • Dermatology Innovation Symposium
    • Dermatology Therapeutics Symposium
  • Archives
  • Contact Us
Picture

Picture

TOP POSTER

Types and Prevalence of Adverse Skin Reactions Associated With N95 and Simple Mask Usage during the COVID-19 Pandemic

Ariel Darnall, DO
View Poster

Characteristics and Treatment of GPP Flares in the US
Zema CL, Valdecantos WC, Weiss J, Krebs B, Menter AM
View Poster

Comparison of GPP patients With and Without Documented Flare Episodes in Their Medical Record
​
Zema CL, Valdecantos WC, Weiss J, Krebs B, Menter AM
View Poster

Medication Use During Hospitalizations for Generalized Pustular Psoriasis
Zema CL, Valdecantos WC, Weiss J, Krebs B, Menter AM, 
View Poster

Appropriate utilization of the prognostic 40-gene expression profile (40-GEP) test for cutaneous squamous cell carcinoma (cSCC) demonstrated by clinical reports and physician evaluation of real-world cases
Aaron S. Farberg, PhD, Jennifer J. Siegel, PhD, Briana Rackley, PhD, Alison L. Fitzgerald, PhD, Sonia K. Morgan-Linnell, Sarah J. Kurley

View Poster

The 31-gene expression profile test stratifies patient risk of recurrence and metastasis in patients with a negative sentinel lymph node biopsy
Brian Martin, Jennifer J. Siegel, Sonia K. Linnell Morgan
View Poster

Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials
Richard Warren, April Armstrong, Melinda Gooderham, Bruce Strober, Diamant Thaçi, Shinichi Imafuku, Howard Sofen, Lynda Spelman, Neil Korman, Min Zheng, Elizabeth Colston, John Throup, Sudeep Kundu, Renata Kisa, Subhashis Banerjee,  Andrew Blauvelt

View Poster

POSTER OF THE DAY - FRIDAY, MARCH 11, 2022

Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo in Scalp, Nail, and Palmoplantar Psoriasis: Subset Analyses of the Phase 3 POETYK PSO-1 and PSO-2 Trials

Richard Warren,  April Armstrong, Melinda Gooderham, Bruce Strober, Diamant Thaçi, Shinichi Imafuku, Howard Sofen, Lynda Spelman, Neil Korman, Min Zheng, Elizabeth Colston, John Throup, Sudeep Kundu, Renata Kisa, Subhashis Banerjee, Andrew Blauvelt
View Poster

Deucravacitinib Long-term Safety in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO Program
Richard B Warren, Howard Sofen, Shinichi Imafuku, Jacek C Szepietowski, Andrew Blauvelt, Lynda Spelman, Jessica Toms, Alex Buck, Subhashis Banerjee, Alan Menter
View Poster

POSTER OF THE DAY - SUNDAY, MARCH 13, 2022
​

Safety and Efficacy of Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, for the Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials

Mark Lebwohl, Leon H. Kircik, Angela Y. Moore, Linda Stein Gold, James Del Rosso, Zoe D. Draelos, Melinda J. Gooderham, Lawrence J. Green, Adelaide A. Hebert, Kim A. Papp, Jerry Bagel, Neal Bhatia, Laura K. Ferris, Terry Jones, Steven E. Kempers, David M. Pariser, Paul S. Yamauchi, Matthew Zirwas, Amy Feng, Patrick Burnett, Robert C. Higham, David R. Berk
View Poster

Patient-reported symptom relief from the Week 28 interim analysis of a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe psoriasis
J Gabriel Vasquez, Neal Bhatia, Paulita Beute, Monique Torres, Brad Schenkel, Stephen J Rozzo, Jayme Heim1
View Poster

Patient satisfaction with tildrakizumab treatment in the Week 28 interim analysis of a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe psoriasis
Jayme Heim, J Gabriel Vasquez, Paulita Beute, Monique Torres, Brad Schenkel, Stephen J Rozzo, Neal Bhatia
View Poster

Efficacy and safety of 1% clascoterone cream through 12 weeks in patients ≥12 years of age with facial acne vulgaris: pooled data analyses of two Phase 3 randomized clinical trials
Martina Cartwright, Luigi Moro, Enrico Fragasso, Jenny Han, Nicholas Squittieri, Alessandro Mazzetti
View Poster

Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Efficacy by Baseline Disease Characteristics and Demographics in Two Pivotal Phase 3 Trials 
Leon Kircik, MD, Linda Stein Gold, MD, James Del Rosso, DO, Seemal R. Desai, MD, Brad P. Glick, DO, Howard Sofen, MD, Anna M. Tallman, PharmD, David S. Rubenstein, MD, PhD, Janine Fournier, PharmD, Philip M. Brown, MD, JD
View Poster

Patient Satisfaction with Tapinarof Cream 1% Once Daily for Plaque Psoriasis in a Long-Term Extension Trial
Jerry Bagel, MD, Linda Stein Gold, MD, James Del Rosso, DO, Neal Bhatia, MD, Sandy Johnson, MD, Paul Yamauchi, MD, PhD,  Angela Y. Moore, MD, Anna M. Tallman, PharmD
View Poster

Efficacy and Safety of Dupilumab in Children Aged ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis
Amy S. Paller, MD, Elaine C. Siegfried, MD, Eric L. Simpson, MD, Andreas Wollenberg, MD, Mercedes E. Gonzalez, MD, Robert Sidbury, MD, Benjamin Lockshin, MD, Yiping Sun, PhD, John T. O’Malley, MD, Ashish Bansal, MD
View Poster

Long-Term Safety Data for Dupilumab up to 4 Years in an Open-Label Extension Study of Adults With Moderate-to-Severe Atopic Dermatitis
Melinda Gooderham, MD, Andreas Wollenberg, MD, Weily Soong MD, Robert Bissonnette, MD, Jing Xiao, PhD, Faisal A. Khokhar, MD, Ainara Rodríguez Marco, MD, Noah A. Levit, MD, Arsalan Shabbir, MD
View Poster

Dupilumab Provides Long-Term Improvement in Sleep Loss in Children, Adolescents, and Adults With Atopic Dermatitis
Mette Deleuran MD, Eric L. Simpson, MD, Amy Praestgaard, MD, Haixin Zhang, Zhixiao Wang, PhD, Ana B. Rossi, MD
View Poster

Dupilumab Monotherapy Provides Long-Term Control and Prevents Flares in Adults With Moderate-to-Severe Atopic Dermatitis Optimally Responding at Week 16
Andreas Wollenberg, MD, Diamant Thaçi, MD, Margitta Worm, MD, Eric L. Simpson, MD, Robert Bissonnette, MD, Amy Praestgaard, MD, Gerald Wilson, PharmD, Ana B. Rossi, MD
View Poster

Efficacy of spesolimab for the rapid control of generalized pustular psoriasis flares: Results from the placebo-controlled Effisayil 1 study
Hervé Bachelez, Jonathan Barker, Kamran Ghoreschi, Boni E. Elewski, Jinhua Xu, Na Hu, Manuel Quaresma, Christian Thoma, Mark G. Lebwohl
View Poster

Insights from patients with generalized pustular psoriasis (GPP): Results of an online survey in the USA
Nirali Kotowsky, Steven R. Brunette, Wendell C. Valdecantos
View Poster

​COVID-19 in tralokinumab-treated patients with moderate-to-severe atopic dermatitis: case series from the ECZTEND long-term extension trial
Andrew Blauvelt, Andrew Pink, Margitta Worm, Richard Langley, Antonio Costanzo, Le Gjerum, Emilie Jorgensen, Joshua Corriveau, Emma Guttman-Yassky
View Poster

Long-term treatment with tralokinumab normalizes the molecular gene signature of atopic dermatitis
Emma Guttman-Yassky, Ana Pavel, Kenji Kabashima, Delphine Staumont-Salle, Kilian Eyerich, Walter Nahm, Sylvia Pauser, Joel Correa Da Rosa, Mads Roepke, Petra Amoudruz, Andrew Blauvelt, Kristian Reich
View Poster

POSTER OF THE DAY - SATURDAY, MARCH 12, 2022

Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial

Amy Paller, Andrew Blauvelt, Weily Soong, Shinichi Imafuku, Chih-ho Hong, Marie L.A. Schuttelaar, Petra Amoudruz, Azra Kurbasic, Lise Soldbro, Katja Lophaven, Michael Cork, Anthony Bewley, Eric L. Simpson
View Poster

Tralokinumab treatment substantially improves patient-reported outcomes in adolescents with moderate-to-severe atopic dermatitis at 16 weeks
Weily Soong, Andrew Blauvelt, Andreas Wollenberg, Chih-ho Hong, Jeffrey Leflein, Anthony Bewley, Petra Amoudruz, Marie Holst Moerch, Lise Soldbro, Shannon Schneider, Eric L. Simpson, Amy Paller
View Poster

Bimekizumab versus ustekinumab in plaque psoriasis: Efficacy translates to sustained improvements in quality of life in the BE VIVID multicentre, randomised, double-blinded phase 3 trial
Peter Foley, Kenneth B. Gordon, Shinichi Imafuku, Joseph F. Merola, Katy White, Veerle Vanvoorden, Fabienne Staelens, Valerie Ciaravino, Mamitaro Ohtsuki
View Poster

Bimekizumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Pooled results from three multicentre, randomised, double blinded phase 3 trials
Lynda Spelman, Richard B. Warren, Bruce Strober, Pablo Fernandez-Peñas, Luke Peterson, Christopher Cioffi, Cynthia Madden, Mamitaro Ohtsuki
View Poster

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 52-Week Results From KEEPsAKE 1
Lars Erik Kristensen , Mauro Keiserman , Kim Papp , Leslie McCasland , Douglas White , Wenjing Lu , Ahmed M Soliman , Ann Eldred , Lisa Barcomb, Frank Behrens
View Poster

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 52-Week Results From KEEPsAKE 2
Andrew Östör , Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Wenjing Lu, Zailong Wang, Ahmed M Soliman, Ann Eldred, Byron Padilla, Alan Kivitz
View Poster

Long-Term Efficacy and Safety of Risankizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: Interim Analysis of the LIMMitless Open-Label Extension Trial Beyond 3.5 Years of Follow-Up
Kim A Papp, Mark G Lebwohl, Lluís Puig, Mamitaro Ohtsuki, Stefan Beissert, Jiewei Zeng, Simone Rubant, Ranjeeta Sinvhal, Ahmed M Soliman, Stefan Beeck, Craig Leonardi
View Poster

Early Ocular Involvement in Granulomatosis with Polyangiitis 
Caroline Brailsford, MS; Chelsea Shope, BA; Laura Andrews, BS;  India Robinson, BA; Alan Snyder, MD, MSCR; Lara Wine Lee, MD, PhD

View Poster

TOP POSTER

​Epidemiological Insight into Acrodermatitis Continua of Hallopeau for Early Diagnosis and Prevention of Disease Progression

Thao Pham, DO; Leon Clark, MD
View Poster

Personalized Medicine for Psoriasis Biologic Treatment
Tobin J. Dickerson, PhD, Byung-In Lee, PhD, Paul Montgomery III, MS, Stephen Boyd, BS, Eric Andrade, BS, Christian Abaya, BS, Courtney Boyce, BS, Tatiana Tomich, MPH, and Yipeng Wang, MD, PhD
View Poster

Dermatologist Concordance with a Precision Medicine Test for the Selection of Psoriasis Biologic Treatment
Bruce E. Strober, MD, PhD, Anish Kunder, Courtney Boyce, Paul Montgomery III, Ann Deren-Lewis, and Tobin J. Dickerson, PhD
View Poster
  • Home
  • Symposia
    • San Diego Dermatology Symposium
    • Dermatology Refresher Symposium for NPs and PAs
    • Dermatology Innovation Symposium
    • Dermatology Therapeutics Symposium
  • Archives
  • Contact Us

Picture